However, the well-described interaction of PrPC with mGluR5 and mechanistic congruency with pharmacologically targeting mGluR5 suggest that the therapeutic effects of Prnp deletion on AD pathology are largely mediated through the Aβo-PrPC-mGluR5 pathway. This evidence concerns the gene ABO and Alzheimer disease.